Financial insights of VCYT

MyFinsight

For the quarter ending 2026-03-31, VCYT made $139,071K in revenue. $28,707K in net income. Net profit margin of 20.64%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue	139,071	140,636	131,872	130,164
Cost of revenue-Testing	33,306	33,712*	33,777	32,407
Cost of revenue-Product	1,891	1,661*	3,015	1,749
Cost of revenue-Biopharmaceutical And Other	8	584*	1,091	3,572
Intangible asset amortization - cost of revenue	2,707	2,707	2,707	2,667
Total cost of revenue	37,912	38,663	40,590	40,395
Gross profit	101,159	101,973	91,282	89,769
Research and development	27,098	20,849	15,981	16,264
Selling and marketing	27,156	25,940	24,455	25,316
General and administrative	23,680	17,367	27,278	32,331
Impairment of assets	-	0*	0	20,505
Intangible asset amortization - operating expenses	579	623*	622	621
Total operating expenses	78,513	64,778	68,336	95,037
Income from operations	22,646	37,195	22,946	-5,268
Other income, net	7,328	3,439	-4,057	6,518
Income before income taxes	29,974	40,634	18,889	1,250
Income tax provision	1,267	-515	-248	2,230
Net income	28,707	41,149	19,137	-980

Basic EPS	0.36	0.52	0.24	-0.01
Diluted EPS	0.35	0.489	0.24	-0.01
Basic Average Shares	79,536,601	79,192,269	78,725,139	78,391,502
Diluted Average Shares	81,313,588	84,153,331	79,691,703	78,391,502

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.